Format

Send to

Choose Destination
J Am Acad Dermatol. 2010 Jun;62(6):957-61. doi: 10.1016/j.jaad.2009.07.042. Epub 2009 Oct 13.

Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications.

Author information

1
Mayo Medical School, College of Medicine, Rochester, Minnesota 55905, USA.

Abstract

BACKGROUND:

Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking.

OBJECTIVE:

We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease.

METHODS:

We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality.

RESULTS:

Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis.

LIMITATIONS:

Retrospective study design and limited patient group are limitations.

CONCLUSIONS:

PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.

PMID:
19828210
DOI:
10.1016/j.jaad.2009.07.042
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center